The company focuses on development of Picoplatin (NX473), a platinum compound, designed to improve efficacy of existing platinum therapeutics for cancer.
Picoplatin, which is in phase II clinical trial stage, is used in solid tumor cancers, including lung cancer and colorectal cancer.
NeoRx was formed in 1984 and is headquartered in Seattle, Washington.
